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Abstract 
Purpose The main purpose of this study was to investigate the effects of a 12-week, clinician referred, 
community-based exercise training program with supervised and unsupervised sessions for men with prostate 
cancer. The secondary purpose was to determine whether androgen deprivation therapy (ADT) modified 
responses to exercise training. 
 
Methods Secondary analysis was undertaken on data from a multicentre cluster randomised controlled trial in 
which 15 clinicians were randomly assigned to refer eligible patients to an exercise intervention (n=8) or to 
provide usual care (n=7). Data from 119 patients (intervention: n=53; control: n=66) were available for this 
analysis. Outcome measures included fitness and physical function, anthropometrics, resting heart rate, and 
blood pressure. 
 
Results Compared to the control condition, men in the intervention significantly improved their six minute walk 
distance (Mdiff=49.98m, padj=0.001), leg strength (Mdiff=21.82kg, padj=0.001), chest strength (Mdiff=6.91kg, 
padj=0.001), 30-second sit-to stand (Mdiff=3.38 reps, padj=0.001), and reach distance (Mdiff=4.8cm, padj=0.024). A 
significant difference (unadjusted for multiplicity) in favour of men in the intervention was also found for 
resting heart rate (Mdiff=-3.76beats.min-1, p=0.034). ADT did not modify responses to exercise training. 
 
Conclusions Men with prostate cancer who act upon clinician referrals to community-based exercise training 
programs can improve their strength, physical functioning, and, potentially, cardiovascular health, irrespective 
of whether or not they are treated with ADT. 
 
Implications for Cancer Survivors Clinicians should inform men with prostate cancer about the benefits of 
exercise, and refer them to appropriately qualified exercise practitioners and suitable community-based 
programs. 
 
Keywords 
prostate cancer; androgen deprivation therapy; aerobic exercise training; resistance exercise training; fitness; 
physical function   
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Introduction 
Prostate cancer is the most frequently diagnosed cancer among men in more developed regions of the world [1], 
with the trend in 5-year relative survival rates approaching 100% in some counties [2-4]. Men with prostate 
cancer typically experience adverse effects associated with the disease and its treatment, however, including 
urinary leakage, bowel urgency, erectile dysfunction [5], fatigue [6], anxiety and depression [7], and diminished 
health-related quality of life [8]. In addition, those treated with androgen deprivation therapy (ADT) are at 
increased risk of bone fracture, muscle mass and strength loss, diabetes, obesity, and cardiovascular-related 
mortality [9, 10]. With this profile of adverse effects, counselling men with prostate cancer to engage in exercise 
training, in combination with other health promoting activities, has been recommended [11]. 
 Exercise training can improve the health and well-being of men with prostate cancer, including aerobic 
fitness, muscular performance (endurance and strength), fatigue, flexibility, body composition (lean body mass), 
blood lipids, and quality of life [12-14]. The evidence is less clear, however, on the effects of exercise training 
on other parameters, such as blood pressure [15-17]. In addition, greater clarity is needed with regard to whether 
responses to exercise training differ between men with prostate cancer receiving ADT and those not receiving 
this treatment. Studies conducted thus far have shown minimal differences between these two cohorts [18, 19]. 
Given the potential of exercise training to reduce the severity of many of the adverse effects of ADT [10], 
identifying differences between these two cohorts in their responses to exercise training would inform the design 
of more effective programs. 
 One of the features of previous studies involving exercise training and prostate cancer is that trials have 
been conducted using supervised (i.e., in the presence of a therapist or exercise physiologist) or unsupervised 
(e.g., home-based without a therapist or exercise physiologist) programs [13, 14]. Demonstrating the 
effectiveness of a combined program has value, as men with prostate cancer are likely to have opportunities to 
undertake supervised and unsupervised exercise training in their communities (e.g., gyms that offer supervised 
classes and unstructured, self-initiated training). There seems to be merit in continuing this line of enquiry 
through designing interventions with features that replicate circumstances that men with prostate cancer are 
likely to experience. 
 With exercise training emerging as a key intervention for improving the lives of men with prostate 
cancer [20], we sought to clarify its effects further in community settings. We report findings from a cluster 
randomised controlled trial of exercise training for men with prostate cancer. This trial had several features that 
enhanced the ecological validity of the intervention: (a) clinicians referred men with prostate cancer to the 
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exercise training program, (b) the program involved both supervised training and unsupervised home-based 
sessions, and (c) the supervised sessions were conducted in community gyms. The primary aim of the study was 
to investigate the effects of the 12-week exercise training program on fitness and physical function, 
anthropometric measurements, resting heart rate, and blood pressure. The secondary aim was to determine 
whether the effects of the program, in term of exercise outcomes, was different for men who received, and those 
who had not received, ADT. 
 
Method 
 
Design 
 
This study represents planned secondary analysis of data from a multicentre, cluster randomised controlled trial 
to determine the efficacy of a clinician referral and 12-week exercise training program for improving exercise 
levels and quality of life for men with prostate cancer. A detailed description of the study methods is available 
from the published protocol [21] and the main outcomes have been published [22]. In brief, 15 clinicians were 
randomised to intervention and control conditions. During consultations, clinicians in both conditions 
determined each patient’s eligibility to participate in the trial. Using short pre-prepared scripts, clinicians 
recommended eligible patients participate in the trial and advised ineligible patients not to participate [21]. 
Clinicians in the intervention condition (n = 8) referred eligible patients to an exercise training program 
involving two supervised sessions in community gyms and one unsupervised home-based session per week. 
Clinicians referred patients using a standardised referral slip, which reiterated the recommendation to participate 
in the exercise training program. Clinicians in the control condition (n = 7) recommended eligible patients 
participate in the trial and provided usual care regarding advice on exercise training (typically, limited amounts 
of information are provided). Clinician adherence to the referral process was monitored weekly with emails and 
personal contact with clinicians at the clinics, checking that they were following the protocol and answering any 
queries that they may have had. The patients in both conditions completed measures associated with the primary 
outcomes of the main study [22], and were also invited to take part in measurements of their fitness and physical 
function, anthropometrics, resting heart rate, and blood pressure. Assessments were conducted before the 
exercise training program begun (baseline) and following the program (12 weeks). 
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 The protocol for this study received approval from the human research ethics committee of the host 
university and those of the healthcare services involved with participant recruitment. Each participant provided 
written informed consent. 
 
Participants 
 
The 15 clinicians involved in this study practised at urology and radiation oncology outpatient clinics across 
three major public health services and four private clinics in Melbourne, Australia. Their patients (n = 741) were 
screened to determine their eligibility for this study (see Table 1).  
 Sample size calculations were based on the primary outcome of the main study (self-reported 
involvement in moderate or strenuous physical activity) [22, 21], rather than the secondary analysis reported 
here.  
 
Exercise training intervention 
 
The 12-week exercise training program involved each participant undertaking two supervised, 50-minute 
sessions at their local community gym and one other home-based session per week. Under the supervision of 
accredited exercise physiologists (tertiary-educated exercise professionals), postgraduate exercise physiology 
students from two universities (in training to become accredited exercise physiologists) supervised participants 
during their gym sessions and provided advice and written instruction for their home-based sessions. The 
exercise training programs were based on exercise training guidelines for cancer survivors from the American 
College of Sports Medicine [23] and Exercise and Sport Science Australia [24]. 
 The supervising accredited exercise physiologists have extensive training and experience working with 
clinical populations, including those with cardiovascular disease, diabetes, cancer, arthritis, and chronic kidney 
disease. The Masters-level students, as part of their regular coursework, received education on exercise 
prescription for people with cancer, as well as on working with various comorbidities that may be present in this 
clinical population. Prior to training participants in this study, students also received an induction from the 
supervising accredited exercise physiologists, during which prescription guidelines and training expectations for 
men with prostate cancer were discussed.  
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 Supervised sessions were performed at community gyms (six YMCA centres and one university-based 
gym) across Melbourne. The YMCA centres and university-based gym represent accessible and affordable 
community gyms. For convenience, participants trained at the community gyms located closest to them. Each 
supervised session included 20-30 minutes of aerobic training, prescribed at 40-70% of maximum heart rate, and 
4-6 upper and lower body resistance training exercises, prescribed as two sets of 8-12 repetitions. To achieve 
consistency in exercise prescription, each participant’s program included a 90° leg press, seated chest press, and 
seated row. The home-based exercise training programs included both aerobic and resistance exercises, with 
body weight and resistance-band exercises prescribed to increase the range of exercises participants could 
perform independently at home. Programs were frequently modified and safely progressed to ensure continual 
fitness gains. 
 
Outcome measures 
 
Fitness and physical function Participants completed five functional exercise tests that are common and safe for 
cancer survivors [25]. Aerobic fitness was assessed using the six minute walk test [26]. Upper and lower body 
maximal strength was measured using a one-repetition maximum protocol [25] with the 90° leg press and seated 
chest press. Lower body muscular endurance was assessed using the 30 second sit-to-stand test [27]. Balance 
was assessed using the functional reach test [28]. 
 
Anthropometrics Height and body mass were measured using a portable stadiometer (220, Seca, Hamburg, 
Germany) and portable scales (UC-321, A&D, Tokyo, Japan), respectively. Body mass index (BMI) was then 
calculated. Girth measurements of chest, waist, hips, upper arm, and mid-thigh were taken using standard 
techniques [29]. 
 
Resting heart rate and blood pressure Assessment of resting heart rate (Electro N2965, Polar, Kempele, 
Finland) and blood pressure (Gamma 4.0 sphygmomanometer, Heine, Herrsching, Germany) were obtained 
manually. Both measures were taken after each participant had been seated for 10 minutes. 
 
Statistical analyses 
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Data were analysed using SAS software, version 9.3 (SAS Institute, Cary, NC). The categorical baseline 
characteristics of participants in the intervention and control conditions were compared using chi-squared and 
Fisher’s exact tests for categorical variables (relationship status, highest level of education, stage of disease, 
treatment regime, ADT, and health service type) and linear mixed models (LMM) with intervention as a fixed 
effect and clinician as a random effect for continuous variables (age, weeks since active treatment, fitness and 
physical function, anthropometrics, resting heart rate, and blood pressure). All LMM analyses conducted in this 
study included clinician as a random effect to account for the clustering due to randomisation at the clinician 
level. 
 The effect of the intervention on changes in fitness and physical function, anthropometrics, resting 
heart rate, and blood pressure between baseline and end of follow up was determined using LMM with clinician 
as a random effect. For this analysis,  missing data at 12-weeks were imputed using the Markov chain Monte 
Carlo algorithm with 20 imputations [30]. 
 To evaluate effect modification of the intervention due to ADT, LMM were fitted with intervention, 
ADT, and the interaction term, intervention×ADT, as fixed effects and clinician as a random effect. 
Due to the effect of multiple comparisons on experiment-wise error (multiplicity), adjusted p values 
were calculated for the 16 tests included in the primary analysis. Both adjusted and unadjusted p values are 
reported for these tests. Adjusted p values were computed using Hommel’s [31] procedure, which has been 
shown to have superior statistical power to the original Bonferroni procedure and similar power to other 
alternatives [32]. 
 
Results 
 
Baseline participant characteristics, attrition, compliance with the intervention, and safety 
 
Of those screened, 147 patients were eligible and agreed to participate in the main study, with 54 referred from 
clinicians randomised to the intervention condition and 93 referred from clinicians in the control condition [22]. 
Of these 147 men, 119 participants (intervention: n = 53; control: n = 66) provided data for this secondary 
analysis. One man withdrew from the intervention condition before baseline data were collected for this 
secondary analysis and 27 men from the control condition gave their consent to participate in the main study on 
the proviso that they did not have to provide physiological data for this secondary analysis. Compared to men 
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who did not provide physiological data, those who did participate in data collection for this secondary analysis 
were 4.2 years older (p = 0.036) and had undergone different treatment regimens (more likely to have had 
surgery and radiotherapy [24.2% vs 0.0%] or radiotherapy and ADT [12.1% vs 0.0%], and less likely to have 
had surgery only [43.9% vs 63.0%], radiotherapy only [16.7% vs 18.5%], surgery, radiotherapy, and ADT 
[3.0% vs 11.1%], or surgery and ADT [0.0% vs 7.4%], p = .0006). In addition, 4.5 weeks more had elapsed 
since active treatment for the men who participated in the data collection (p = 0.032). 
No significant differences between the intervention and control conditions were observed for any 
participant characteristic (see Table 2). Of the 119 participants, 11 men (intervention: n = 6; control: n = 5) 
withdrew or were lost to follow up (refer to main study paper for details [22]). In comparison to those who 
underwent assessment at 12 weeks, those who did not attend this assessment had larger chests and waists, as 
well as higher diastolic blood pressure at baseline (p < .05 for all). No other statistically significant differences 
were found. Comparisons of the non-attendees from the intervention (n = 6) and control (n = 5) conditions 
yielded no statistically significant differences (the power to detect such differences was low, however). 
 At baseline, compared with men not receiving ADT, those receiving ADT were older (Mdiff = 7.3 years, 
95% CI [3.4, 11.2], p < 0.0001), had higher systolic blood pressure (Mdiff = 8.4mm Hg, 95% CI [1.6, 15.2], p = 
0.016), walked less distance over six minutes (Mdiff = -44.5m, 95% CI [-83.8, -5.2], p = 0.027), and had lower 
chest strength (Mdiff = -13.6kg, 95% CI [-25.2, -2.0], p = 0.022) and leg stremgth (Mdiff = -43.4kg, 95% CI [-
68.1, -18.8], p = 0.0007). In addition, for men receiving ADT, more time had elapsed since active treatment 
(Mdiff = 5.9 weeks, 95% CI [0.5, 11.3], p = 0.034). 
 As has been reported previously, 85% of the men in the intervention condition undertook at least 18 of 
the 24 supervised sessions in their local community gyms and, of those who completed their exercise diaries 
(74%), 81% completed at least 9 of 12 home-based sessions [22].  
Adverse events (musculoskeletal injuries) were reported for two participants. One man in the 
intervention condition aggravated a previous rotator cuff injury (left shoulder, equivalent to a grade I strain) 
during exercise training. The other man, in the control condition, aggravated a previous right knee injury 
(meniscus tear) during baseline testing. 
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Fitness and physical function  
 
Sizable, statistically significant differences between conditions were observed, in favour of men in the 
intervention condition for all measures of physical functioning (Table 3).  
 Examinations of the possible modifying effect of ADT treatment on the intervention effect revealed 
minimal, non-significant differences between men receiving ADT and those not receiving this treatment. The 
mean intervention effects were similar for six minute walk distance (ADT: 59.7m, 95% CI [11.8, 107.5]; non-
ADT: 47.5m, 95% CI [21.8, 73.2]; p = 0.673), leg strength (ADT: 13.7kg, 95% CI [-8.4, 35.8]; non-ADT: 
25.2kg, 95% CI [13.9, 36.5]; p = 0.370), chest strength (ADT: 8.5kg, 95% CI [-0.7, 17.7]; non-ADT: 7.1kg, 
95% CI [2.7, 11.4]; p = 0.788), 30-second sit-to-stand result (ADT: 4.0 reps, 95% CI [0.4, 7.6]; non-ADT: 3.4 
reps, 95% CI [1.5, 5.2]; p = 0.778), and reach distance (ADT: 7.1cm, 95% CI [-0.1, 14.4]; non-ADT: 4.1cm, 
95% CI [0.5, 7.7]; p = 0.487). 
 
Anthropometrics 
 
Differences between conditions were minimal and none were statistically significant (Table 3). Changes over 
time were also minimal, with the only statistically significant result (unadjusted p only) being a 1.4cm mean 
average reduction in hip circumference for the men in the intervention condition. 
 
Resting heart rate and blood pressure 
 
The resting heart rates of the men in the intervention condition decreased by 3.76 beats.min-1 more than those of 
men in the control condition (see Table 3).  
 
Discussion 
 
This trial demonstrates that the fitness and physical functioning of men with prostate cancer can be 
enhanced through an exercise training program with features that many men could encounter during their 
clinical care and within their communities. The intervention commenced with the referral of men with prostate 
cancer to an exercise training program – an initiative that is consistent with guidelines recommending clinicians 
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counsel prostate cancer survivors to engage in at least 150 minutes of physical activity per week [11]. At 
present, no direct formalised pathway exists between oncology clinicians and allied health providers in 
Australia. People with chronic conditions and complex care needs (including people with cancer), however, may 
each be eligible for Medicare rebates for up to five allied health consultations per calendar year (including with 
accredited exercise physiologists [33]) through referrals from general practitioners. Enabling direct referrals 
between oncology clinicians and allied health professionals, such as exercise physiologists, would facilitate 
earlier intervention and improve access to exercise training programs for men with prostate cancer. The 
combination of supervised and unsupervised sessions also matches the reality that most men will be able to 
access practical support for their physical activity participation from their local communities. Community gyms 
(and many commercial ones), for example, typically assist members through writing exercise programs for 
them, providing periodic program reviews, having staff available to demonstrate correct exercise techniques, 
and running group exercise classes. In addition, YMCA Australia recently announced a commitment to 
employing accredited exercise physiologists in over 30 facilities by the end of 2018. This development will 
increase the accessibility of quality support and advice for men with prostate cancer who wish to follow 
recommendations to be physically active. 
 Participation in the exercise training improved the aerobic capacity of men with prostate cancer. Not 
only did the men improve the distances walked over six minutes, they were also observed to have lower resting 
heart rates at 12 weeks, which is a common adaption of aerobic exercise training [34]. For the six minute walk 
distance, the improvements (ADT: 59.7m; non-ADT: 47.5m) were in excess of the recommended criterion for 
meaningful change in older adults (20m) and consistent with the criterion for substantial meaningful change 
(50m) [35]. Given that the participants were already quite physically active at baseline [22] and typically did not 
attend all the scheduled sessions, these results may be particularly impressive. With regard to the baseline scores 
for the six minute walk, for example, the men in this study covered more distance than men with prostate cancer 
in other studies [36, 37].  
 The men who participated in the exercise training increased their upper and lower body strength. Given 
that few randomised controlled trials focusing on these outcomes included men not treated with ADT [38], these 
observations are an important contribution to the literature. Developing and maintaining muscle strength is 
imperative, because low muscle strength is an independent predictor of impaired mobility [39] and all-cause 
mortality [40] in older adults. Consistent with current guidelines [11], clinicians should counsel men with 
prostate cancer to include resistance exercises as part of their training programs. 
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 Encouraging men with prostate cancer to incorporate resistance exercises as part of their training also 
provides opportunities for their strength to be monitored (e.g., by exercise physiologists or trainers) and this 
information shared with clinicians. Muscle strength is a better predictor of morbidity and all-cause mortality 
than muscle mass [39, 40], and the assessment of muscular strength is more feasible than common measures of 
muscle mass (e.g., via dual-energy x-ray absorptiometry). The assessment of muscular strength could be a 
valuable outcome from a referred exercise training program, because it could be used for risk stratification and 
further clinical interpretations. 
The effect of the intervention on systolic blood pressure was less pronounced and not statistically 
significant, but is a finding that warrants further investigation. Previous research on men with prostate cancer 
have generally shown exercise to have no significant effect on systolic blood pressure [17, 41, 15, 16]. Control 
condition contamination, however, has been cited as a possible reason for the non-significant findings in studies 
of exercise and prostate cancer [41]. The magnitude of the intervention effect (-3.82 mm Hg) is slightly higher 
than reductions achieved for adults without cardiovascular or other diseases who participate in dynamic 
resistance training (-1.8 mm Hg) [42]. One reason for the muted response may be that the resting systolic blood 
pressure was not high at baseline (intervention: M = 134.6, SD = 11.5; control: M = 136.6, SD = 11.9), with 
some evidence suggesting that, for people aged over 50, systolic blood pressure <140 mm Hg should be 
considered normal [43]. Although lowering systolic blood pressure when it is already <140 mm Hg may have 
limited health benefits (compared with reducing systolic blood pressure to 140-160mm Hg or 140-149mm Hg) 
[44], changes of the magnitude observed in the present trial may be clinically meaningful with men who have 
higher systolic blood pressure.  Clinicians and researchers are encouraged to continue investigations on the 
effect of exercise training on blood pressure in men with prostate cancer. 
The detrimental effect of ADT on fitness and physical functioning observed previously [36, 45, 46] 
was also evident in the present study. At baseline, men receiving ADT had less strength, walked shorter 
distances over six minutes, and had higher systolic blood pressure than those not treated with ADT. Recent 
research has shown that declines in physical function with ADT do not recover over a 36 month period [36], 
which underscores the importance of using exercise training as a counteractive measure.  
 Men treated with ADT responded to the exercise training similarly to men who had not been treated 
with ADT. This finding adds weight to the small amount of previous research showing minimal, and statistically 
non-significant, differences between men receiving ADT and those not undergoing this treatment in terms of 
their responses to exercise training [18, 19]. Although some caution is appropriate when interpreting these 
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findings (due to the comparatively low number of men receiving ADT recruited for the present study), it should 
be noted that the differences were essentially in favour of men receiving ADT. 
 A limitation of this trial was that men recruited were more physically active than those reported in 
other studies [47]. Higher physical activity levels at baseline may have attenuated the magnitude of the effects 
that may have otherwise been achieved through such an intervention with less active men with prostate cancer. 
If the men had been less active at baseline, clearer effects may have been observable with respect to resting 
heart rate, systolic blood pressure, and waist circumference. In addition, as has been mentioned, the 
comparatively small number of men receiving ADT recruited into this study was another limitation. A larger 
sample of men with ADT in this study would have enabled firmer conclusions to be drawn about the effects of 
ADT on men’s responses to exercise. 
 Despite these limitations, the trial demonstrated that clinician referral to a community-based exercise 
training intervention with supervised and unsupervised sessions can have clear benefits for men with prostate 
cancer, both in terms of their physical function and, possibly, their cardiovascular health. The findings also 
suggest that favourable outcomes were gained irrespective of whether or not men were treated with ADT. These 
results should encourage clinicians to inform their patients with prostate cancer about the benefits of exercise 
and to ensure they are able to refer them to appropriately qualified exercise practitioners or other supervised 
exercise training programs to develop suitable exercise regimens for these men. 
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Table 1 Study inclusion and exclusion criteria 
Inclusion criteria 
 Diagnosed with stage I, II, or III cancer 
 Completed active treatment for prostate cancer within the previous 3-12 months (patients on 
hormone treatment were eligible to participate) 
 The ability to complete surveys in the English language  
Exclusion criteria 
 Any musculoskeletal, cardiovascular, or neurological disorders that could limit exercising 
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Table 2 Baseline participant characteristics 
 Characteristics Intervention (n = 53)  Control (n = 66) pa 
 Mean±SD or n (%) Mean±SD or n (%)  
Demographic characteristics    
   Age (years) 66.8±8.3 66.0±8.1 0.276 
   Relationship status   0.809 
      Married 41 (78.8) 47 (73.4)  
      De facto or living with partner 3 (5.8) 6 (9.4)  
      Separated, divorced, widowed, or not living with partner 8 (15.4) 11 (17.2)  
   Highest level of education   0.974 
      Primary school 3 (5.8) 4 (6.3)  
      Secondary school 15 (28.8) 17 (27)  
      Certificate or diploma 18 (34.6) 24 (38.1)  
      University degree 16 (30.8) 18 (28.6)  
Clinical characteristics    
   Stage of disease   0.075 
       Stage I 19 (46.3) 22 (36.7)  
       Stage II 11 (26.8) 29 (48.3)  
       Stage III 11 (26.8) 9 (15)  
   Treatment regime   0.347 
       Surgery only 18 (34) 29 (43.9)  
       Radiotherapy only 5 (9.4) 11 (16.7)  
       Surgery and radiotherapy 15 (28.3) 16 (24.2)  
       Radiotherapy and androgen deprivation therapy 12 (22.6) 8 (12.1)  
       Surgery, radiotherapy and androgen deprivation therapy 3 (5.7) 2 (3)  
   Androgen deprivation therapy    
      No 38 (71.7) 56 (84.8) 0.112 
      Yes 15 (28.3) 10 (15.2)  
   Weeks since active treatment  25.3±11.4 26.5±9.4 0.586 
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   Health service type    
       Public 39 (73.6) 50 (75.8) 0.834 
       Private 14 (26.4) 16 (24.2)  
Physical function    
   6 minute walk distance (m) 543.7±81.8 551.7±67.9 0.793 
   Leg – 1 repetition maximum (kg)  126.1±46.0 136.8±42.7 0.181 
   Chest  – 1 repetition maximum (kg) 60.5±22.8 60.0±21.6 0.540 
   30-second sit-to-stand (n) 14.2±3.6 14.8±4.1 0.395 
   Reach distance (cm) 36.4±5.8 38.2±7.8 0.331 
Anthropometrics    
   Body mass index (kg/m2) 28.5±3.7 28.9±4.0 0.510 
   Chest circumference (cm) 101.9±7.7 102.4±8.3 1.000 
   Waist circumference (cm) 97.7±9.9 98.3±10.6 0.693 
   Hip circumference (cm) 102.2±6.5 103.1±7.7 0.671 
   Right thigh circumference (cm) 47.9±4.4 49.0±4.7 0.365 
   Left thigh circumference (cm) 47.9±4.2 48.6±4.5 0.490 
   Right arm circumference (cm) 30.5±2.9 30.8±3.1 0.723 
   Left arm circumference (cm) 30.1±3.2 30.5±3.1 0.583 
Resting heart rate and blood pressure    
   Resting heart rate (beats/min) 71.2±10.9 72.0±13.3 0.444 
   Systolic blood pressure (mm Hg) 134.6±11.5 136.6 (11.9) 0.942 
   Diastolic blood pressure (mm Hg) 83.1±8.5 84.5±8.2 0.448 
a Fisher’s exact test for categorical variables, linear mixed model including intervention as fixed effect and clinician as random effect for numerical variables. No adjustments 
were made for multiplicity. 
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Table 3 Changes in fitness and physical function, anthropometrics, resting heart rate, and blood pressure, and from baseline to 12 weeks: Comparison between conditions 
Variable Mean change (95% CI)  Mean intervention effect (95% CI) 
 Intervention (n = 53) Control (n = 66)  Intervention - control pa padjb 
Fitness and physical function       
   Six minute walk distance (m) 64.87 (49.76, 79.99) 14.89 (0.47, 29.31)  49.98 (28.54, 71.42) <0.0001 0.001 
   Leg – 1 repetition maximum (kg)  28.54 (21.54, 35.54) 6.72 (-0.06, 13.49)  21.82 (12.15, 31.49) <0.0001 0.001 
   Chest  – 1 repetition maximum (kg) 10.05 (7.30, 12.80) 3.14 (0.59, 5.69)  6.91 (3.31, 10.51) <0.0001 0.001 
   30-second sit-to-stand (reps) 3.89 (2.8, 4.99) 0.51 (-0.54, 1.56)  3.38 (1.87, 4.89) <0.0001 0.001 
   Reach distance (cm) 3.17 (0.92, 5.41) -1.63 (-3.71, 0.45)  4.80 (1.77, 7.82) 0.002 0.024 
Anthropometrics       
   Body mass index (kg/m2) -0.02 (-0.24, 0.20) 0.05 (-0.15, 0.24)  -0.07 (-0.36, 0.23) 0.654 0.788 
   Chest circumference (cm) -0.75 (-1.66, 0.16) -0.01 (-0.82, 0.79)  -0.74 (-1.96, 0.49) 0.238 0.788 
   Waist circumference (cm) -1.06 (-2.21, 0.10) 0.06 (-0.98, 1.09)  -1.11 (-2.68, 0.46) 0.165 0.788 
   Hip circumference (cm) -1.4 (-2.35, -0.46) 0.25 (-0.61, 1.11)  -1.65 (-2.95, -0.35) 0.013 0.143 
   Right thigh circumference (cm) 0.55 (-0.15, 1.25) 0.24 (-0.42, 0.90)  0.31 (-0.65, 1.27) 0.526 0.728 
   Left thigh circumference (cm) 0.66 (-0.03, 1.34) 0.35 (-0.27, 0.97)  0.31 (-0.64, 1.25) 0.523 0.788 
   Right arm circumference (cm) -0.39 (-0.99, 0.21) -0.28 (-0.81, 0.25)  -0.11 (-0.92, 0.70) 0.788 0.788 
   Left arm circumference (cm) -0.34 (-0.92, 0.25) -0.20 (-0.72, 0.32)  -0.14 (-0.93, 0.65) 0.733 0.788 
Resting heart rate and blood pressure       
   Resting heart rate (beats/min) -4.21 (-6.76, -1.66) -0.45 (-2.80, 1.90)  -3.76 (-7.23, -0.28) 0.034 0.306 
   Systolic blood pressure (mm Hg) -2.04 (-4.86, 0.79) 1.78 (-0.71, 4.28)  -3.82 (-7.65, 0.02) 0.051 0.459 
   Diastolic blood pressure (mm Hg) -1.31 (-3.52, 0.90) 0.72 (-1.25, 2.70)  -2.03 (-5.00, 0.93) 0.179 0.788 
ap values are unadjusted for multiplicity. 
bp values are adjusted for multiplicity using Hommel’s [31] procedure. 
 
